Appointment supports Respiratory Programme Advancement

Dr Niyati Prasad, who has more than 20 years’ experience of clinical developments in immunology, respiratory and rare diseases, has joined Enterprise Therapeutics as Chief Medical officer, to advance its programmes aiming to improve the lives of patients suffering from respiratory disease. The company is developing therapies targeting the underlying mechanisms of mucus congestion and later this year its ETD001 ENaC inhibitor  will be evaluated in a CF Phase 2 clinical trial.

Formerly Senior Director of Clinical Development at GSK, Dr Prasad has also held various leadership roles at large biopharmaceutical organisations, including Galapagos, Vertex, Takeda and Novartis, where she oversaw drug development teams and programmes for diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), successfully progressing several therapeutics through regulatory approvals.

Dr Prasad received her Medical Degree from Gauhati Medical College, India, and her Diploma in Pharmaceutical Medicine from Universite Libre De Bruxelles. She also completed a Masters in Drug Development Science at Kings College London.

Dr John Ford, CEO, Enterprise Therapeutics, said: “Niyati’s long-standing expertise in respiratory drug development and impressive track record in directing clinical programmes will be an invaluable asset to Enterprise. We are confident that Dr Prasad will play a key role in progressing our novel respiratory therapies through the clinic.”

Dr Niyati Prasad, CMO, Enterprise Therapeutics, commented: “Enterprise is a dynamic and exciting company, with its programmes offering huge potential, especially in the treatment of cystic fibrosis regardless of underlying mutations. I look forward to working closely with the team to bring these novel therapies for respiratory disease to patients.”

More information online